Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Sorafenib is being looked at in a number of solid tumor settings including breast cancer.
This trial is designed as a pilot study to assess the safety and tolerability of a novel oral
agent in combination with standard chemotherapy in the treatment of early stage node positive
or otherwise high-risk breast cancer. If this should prove to be a tolerable regimen for
patients, this would provide rationale for further studies in a larger randomized fashion.